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Abstract 
Human noroviruses (NoVs) are a major cause of gastroenteritis worldwide. It is thought that, 
similar to other RNA viruses, high mutation rates allow NoVs to evolve fast and to undergo 
rapid immune escape at the population level. However, the rate and spectrum of spontaneous 
mutations of human NoVs has not been quantified previously.  Here, we analysed the intra-
patient diversity of the NoV capsid by carrying out RT-PCR and ultra-deep sequencing with 
100,000-fold coverage of 16 stool samples from symptomatic patients. This revealed the 
presence of low-frequency sequences carrying large numbers of U-to-C or A-to-G base 
transitions, suggesting a role for hyper-mutation in NoV diversity.  To more directly test for 
hyper-mutation, we performed transfection assays in which the production of mutations was 
restricted to a single cell infection cycle. This confirmed the presence of sequences with 
multiple U-to-C/A-to-G transitions, and suggested that hyper-mutation contributed a large 
fraction of the total NoV spontaneous mutation rate. The type of changes produced and their 
sequence context are compatible with ADAR-mediated editing of the viral RNA.  
 
Graphical abstract: this optional item will be prepared and submitted upon manuscript 
acceptance. 
 
Keywords: hyper-mutation, next-generation sequencing, norovirus, RNA virus.  
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1. Introduction 
Noroviruses (NoVs) are one of the most common causes of foodborne viral gastroenteritis, 
infecting over 250 million people worldwide every year. Symptoms typically last 24 to 48 h, but 
complications can occur in immunocompromised patients, resulting in an estimated 200,000 
deaths per year mainly among elderly people and young children in developing countries 
(Patel et al. 2008; Robilotti et al. 2015). NoVs are positive-stranded RNA viruses belonging to 
the family Caliciviridae and, similar to other RNA viruses, they exhibit extremely high levels of 
genetic diversity (Debbink et al. 2012). NoVs have evolved into seven highly divergent 
genogroups (GI-GVII), which are in turn divided into genotypes. The prototypic Norwalk virus 
belongs to genotype GI.1, but GII.4 has become the most prevalent genotype in the last 
decades, being responsible for the majority of outbreaks (White 2014). The most variable NoVs 
genome regions are located in the surface-exposed P2 domain of the capsid (VP1) protein, 
which determines antibody escape (Lindesmith et al. 2008; White 2014). Differences in genetic 
diversity and evolution rates among NoV genotypes have been attributed to multiple factors, 
including random genetic drift, receptor usage, the structural plasticity of the VP1 protein, and 
replication fidelity (Bull and White 2011; Donaldson et al. 2010). However, and despite their 
purported importance for evolution, immune escape, and the development of efficient control 
strategies, the rate of spontaneous mutation of human NoVs has not been experimentally 
determined.  
RNA virus high genetic diversity is ultimately driven by their extremely high rates of 
spontaneous mutation, which are orders of magnitude higher than those of DNA-based 
microorganisms and range from 10–6 to 10–4 per nucleotide per round of copying (Lauring et al. 
2013; Sanjuán et al. 2010). Such high mutation rates are commonly attributed to the low 
replication fidelity of RNA virus polymerases, since these lack 3´exonuclease activity in all viral 
families examined except coronaviruses (Smith and Denison 2013; Ulferts and Ziebuhr 2011). 
However, editing of the viral genome by host-encoded proteins is another possible source of 
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mutations. Double-stranded RNA-specific adenosine deaminases (ADAR) have been suggested 
to edit the genome of a variety of negative-stranded RNA viruses, including measles virus 
(Cattaneo et al. 1988), human parainfluenza virus (Murphy et al. 1991), respiratory syncytial 
virus (Martinez and Melero 2002), lymphocytic choriomeningitis virus (Zahn et al. 2007), and 
Rift Valley fever virus (Suspene et al. 2008), and the apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3 cytidine deaminase family (APOBEC3) is known to edit HIV-1 
(Desimmie et al. 2014; Moris et al. 2014; Santa-Marta et al. 2013), hepatitis B virus (Suspene et 
al. 2005), papillomaviruses (Vartanian et al. 2008), and herpesviruses (Suspene et al. 2011). In 
HIV-1, 98% of spontaneous mutations in vivo are produced by APOBEC3, whereas only 2% are 
attributable to the viral reverse transcriptase (Cuevas et al. 2015), but the relative contribution 
of the viral polymerase and host-mediated editing is unknown for most other viruses.  
Here, we have analysed the intra-patient genetic diversity of a region of the NoVs 
capsid VP1 by performing ultra-deep sequencing of stool samples obtained from infected 
patients. Unexpectedly, we found a small number of hyper-mutated sequences carrying large 
numbers of A-to-G or U-to-C base transitions that were not attributable to sequencing errors. 
In this sense, since the per-base error rate of the employed technology is ca. 1/1000 
(Jünemann et al. 2013), it is extremely improbable to find multiple mutations in a single read. 
The natural genetic diversity of NoVs has been studied previously within individual patients 
(Nilsson et al. 2003; Obara et al. 2008; Vega et al. 2014), within defined outbreaks (Dingle 
2004; Holzknecht et al. 2015; Sasaki et al. 2006), or at larger geographic and temporal scales 
(Bodhidatta et al. 2015; Carlsson et al. 2009; Cotten et al. 2014; Kobayashi et al. 2015; Vega et 
al. 2014). However, this diversity depends on multiple factors other than spontaneous 
mutation rates, including natural selection, the number of replication rounds elapsed and 
random genetic drift, among others. To discard these confounders and focus on spontaneous 
mutations, we used a cell culture system in which human cells are transfected with an 
infectious cDNA clone (Asanaka et al. 2005; Katayama et al. 2014). Since these cells do not 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
5 
 
support viral attachment and entry, this system restrict viral replication to a single infection 
cycle. Whereas this is generally viewed as a limitation, single-cycle viral replication was 
convenient for the purpose of mutation rate estimation, because it allowed us to minimize the 
effects of selection and other evolutionary factors. This approach allowed us to observe 
hundreds of sequences carrying multiple U-to-C or A-to-G substitutions each, suggesting that a 
large fraction of all spontaneous mutations correspond to hyper-mutation events. Based on 
the sequence context of the observed changes, we propose that NoV hyper-mutation might be 
driven by ADAR-mediated editing of the viral genomic RNA of either polarity during replication. 
2. Methods  
2.1. RT-PCR of stool samples.  
Viral RNA was extracted from 20% stool suspensions in PBS using the Trizol LS reagent 
(Invitrogen), eluted in diethyl pyrocarbonate-treated water containing RNasin (Promega) and 
stored at –70°C. RT was performed using Superscript III (Invitrogen) and random hexamers for 
10 min at 25°C, 45 min at 50°C and 15 min at 70°C. PCR was done with Phusion High-Fidelity 
DNA polymerase following manufacturer´s recommendations and specific primers 
degenerated either for purines or pyrimidines at a final concentration of 200 µM. For VP1 
region 1, two pairs of primers with different degeneration were used: primers 5’-
AyGAAGAyGGCGyCGAGyGACG-3’ (forward, nucleotides 5085-5106 in accession JX459908) and 
5’-GGrrrrTTTGGTGGGrCTGCTGC-3’ (reverse, nucleotides 5448-5470 in accession JX459908) 
were designed to account for U-to-C mutations in plus-strand RNA, and primers 5’-
rTGrrGrTGGCGTCGrGTGrCG-3’ (forward) and 5´-GGAAAAyyyGGyGGGACyGCyGC-3’ (reverse) 
were designed to account for A-to-G mutations in plus-strand RNA. For region 2, the 
degenerate primer pairs were 5’-CAAGAyyCCCCAyyCCyyyGG-3’ (forward, nucleotides 5803-
5823 in accession JX459908) and 5’-GGrTGrCrCCGrCTGGGGTG-3’ (reverse, nucleotides 6233-
6252 in accession JX459908), and 5’-CrrGrTTCCCCrTTCCTTTGG-3’ (forward) and 5’-
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GGAyGACACCGACyGGGGyG-3’ (reverse), respectively.  PCR conditions were 98°C 30 s, 35 
cycles of 98°C 10 s, 68°C 30 s, 72°C 1 min, and a final elongation step at 72°C 5 min. 
2.2. Transfection assays.  
A previously described Norwalk virus infectious cDNA clone (Asanaka et al. 2005) was obtained 
after an MTA with Dr. M. K. Estes (Baylor College of Medicine, Houston), cloned in E. coli by the 
heat shock method, and purified by midiprep using the PureLink HiPure Plasmid Midiprep kit 
(Invitrogen). Human embryonic kidney cells HEK293 were obtained from the American Tissue 
Culture Collection (ATCC CRL-11268) and cultured in DMEM F12 (Dulbecco’s modified Eagle 
medium) supplemented with 10% FBS and antibiotics at 37°C under 5% CO2. Norovirus was 
recovered from the cDNA clone as described previously (Asanaka et al. 2005). Briefly, 
approximately 105 HEK293 cells (80% confluence) were infected with a recombinant vaccinia 
virus expressing bacteriophage T7 RNA polymerase at a multiplicity of infection of 10 plaque-
forming units per cell and, after 1 h incubation, the inoculum was washed and cells were 
transfected with 0.5 µg of the infectious cDNA clone using Lipofectamine LTX Reagent 
(Invitrogen), following manufacturer´s instructions. After 5 h incubation at 37°C, vaccinia 
replication was inhibited with 25 g/mL AraC (arabinofuranosyl cytidine) and cells were 
incubated for 48 h. A plasmid containing a green-fluorescent-protein (GFP) transfected under 
the same conditions was used as a transfection control. 
2.3. RT-PCR of NoV RNA extracted from HEK293 cells.  
After 48 h incubation, RNA was extracted from transfected cultures using TRIzol (Invitrogen) 
followed by chloroform and isopropanol purification, and washed with 75% ethanol. In order 
to digest any remaining DNA, samples were treated with 1 U/µg RNase-free DNase I (Thermo 
Scientific) for 30 min at 37°C. DNase I was heat-inactivated (10 min at 65°C) and the RNA was 
column-purified using NucleoSpin RNA Clean-up XS kit (Macherey-Nagel). Purified RNA was 
reverse-transcribed using Accuscript High Fidelity Reverse Transcriptase (Agilent Technologies) 
and a sequence-specific primer. Negative-strand RNA was reverse-transcribed using the 
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following primer 5’-ATTACTCTCTGTGCACTGTCTG-3’ (nucleotides 4790-4811 in accession 
NC_001959), whereas positive-strand RNA was reverse-transcribed using primer 5’-
CAGTGTAGAAGAGGCTGTTGAA-3’ (nucleotides 7501-7522 in accession NC_001959). Reverse 
transcription conditions used were 42°C for 60 min, followed by 70°C at 15 min. The VP1 gene 
was then PCR-amplified using Phusion High Fidelity DNA polymerase (New England Biolabs) 
and primers 5’-GACGCyACAyCAAGCGyGG -3’ (forward, nucleotides 5376-5394 in accession 
NC_001959) and 5’- CTCrTGTTrCCrrCCCrrCC -3’ (reverse, nucleotides 5661-5680 in accession 
NC_001959). The PCR conditions used were 98°C 30 s, 35 cycles at 98°C 10 s, 59°C 30 s, and 
72°C 1 min, and a final extension at 72°C 10 min. Controls were carried out in which the PCR 
was performed without RT step to ensure that no remaining DNA from the infectious clone 
was amplified. To control for strand-specific amplification, transfection supernatants were 
cleaned by centrifugation at 16,000 × g, 15 min, 4°C to separate free virions containing plus-
strand genomes from cellular pellets, used for RNA extraction, and the RT step was performed 
with the same primer used for amplification of minus strands. As expected, these controls did 
not yield any visible PCR product. To obtain a shorter product for Illumina sequencing, a 
secondary PCR of the indicated size was done with the following cycling conditions: 98°C 30 s, 
40 cycles of 98°C 10 s, 60°C 30s, 72°C 1min, and a final extension at 72°C 5 min.  
2.4. Illumina sequencing.  
PCR products were sequenced in an Illumina Miseq machine using paired-end libraries. The 
quality of the run was first evaluated with FastQC software 0.10.1 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). For clinical samples, a base 
calling pipeline was run to define a consensus reference sequence for each sample. To do this, 
Illumina adapters and PCR primers were cut with Cutadapt software (Marcel 2011), fastq files 
were trimmed using Prinseq-lite version 0.20.4 (Schmieder and Edwards 2011), mapping was 
done using the Mem algorithm from Bwa 0.7.12 (http://arxiv.org/abs/1303.3997), SAM files 
were converted to BAM format, sorted and indexed using SAMtools software package (Li et al. 
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2009), and  sequence variants relative to a common reference were called with VarScan 2.3.7 
(Koboldt et al. 2013) using SAMtools mpileup data as input. For each sample, nucleotide 
changes detected at a frequency higher than 0.5 were used to construct the sample-specific 
reference sequence. For subsequent steps, paired-end Illumina reads were merged using 
PANDAseq (Masella et al. 2012) and an initial trimming of these merged fastq files was 
performed with Prinseq-lite version 0.20.4. Trimmed fastq files were converted into fasta and 
standalone blast pair-wise alignments (Camacho et al. 2009) were obtained to map reads and 
to obtain the number of mutations relative to the reference sequence of the sample. Since the 
number of reads was variable, 100,000 reads were randomly chosen for each PCR. To obtain a 
refined set of mutated reads, a final quality filter was applied, such that only reads with 
average Phred quality score higher than 28 for the specific mutated positions were considered. 
This filter removed less than 5% of the original reads in all samples. Specific Shell, Python, Perl 
and R scripts were written for these analyses. 
2.5. Molecular cloning and Sanger sequencing of PCR products.  
PCR products were gel-purified and cloned using CloneJET PCR cloning kit (Thermo Scientific) in 
E.coli by the heat shock method. Transformant colonies were PCR-amplified using Taq DNA 
polymerase and CloneJET-specific primers (forward 5’-CGACTCACTATAGGGAGAGCGGC-3’; 
reverse 5’-AAGAACATCGATTTTCCATGGCAG-3’) under the following conditions: 95°C 5 min, 35 
cycles of 95°C 30 s, 60°C 30 s, 72°C 2 min, and a final extension at 72°C 5 min. Colony PCR 
products were column-purified and sequenced by the Sanger method. Sequence 
chromatograms were analysed using the Staden software (http://staden.sourceforge.net). 
 
3. Results 
3.1. Ultra-deep sequencing reveals NoV hyper-mutants in clinical samples.  
We used 16 stool samples from patients acutely infected with NoV GII.4 to amplify by RT-PCR a 
386-base region encompassing nucleotides 1 to 386 of the VP1 gene (reference sequence: 
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GenBank JX459908; Fig. 1A). The RT-PCR was successful in 11/16 samples. Of these, eight 
belonged to newborns or children under the age of three, two to adults, and for one sample 
there was no available age information. We performed paired-end Illumina sequencing of 
these PCR products with 100,000-fold coverage (i.e. 100,000 reads per patient).  For three 
patients, approximately one in 6000 reads contained large numbers of U-to-C or A-to-G base 
transitions (12-27 reads with 5-30 such mutations out of approx. 100,000 total reads; Table 1). 
Reads with less than five mutations of such type were not considered as hyper-mutants. 
Although the error rate of Illumina sequencing precludes analysis of low-frequency 
polymorphisms, it provides a powerful approach for detecting hyper-mutants. In the most 
mutated read, 30 of the 86 U residues were substituted for C, a pattern that cannot be 
explained by sequencing error. Interestingly, we found both U-to-C and A-to-G hyper-
mutations, but these did not occur in the same reads. To extend our analysis, we set out to 
amplify by RT-PCR another region encompassing nucleotides 719 to 1168 of VP1 (450 bases, 
although only the 409 bases excluding primer regions were considered for subsequent 
analysis), which maps to the hypervariable domain P2. In two out of the three samples 
showing hyper-mutation in the first region, we also found hyper-mutated reads in the second 
region, with a maximum of 37 mutations in a single read. Furthermore, one sample which 
failed to amplify for the first region also yielded hyper-mutated reads in the second region 
(Table 1).  Two of the samples showing hyper-mutation belonged to newborns, whereas the 
other two belonged to adults, with no significant association between age and hyper-mutation 
at this low sample size (Fisher’s exact test, P = 0.547).  Viruses carrying large numbers of 
mutations should not be viable and, thus, their population frequency should be strongly 
reduced by the action of purifying selection. Therefore, albeit very rare, hyper-mutants may 
reflect a relevant mutational process in NoV.  
3.2. Massive hyper-mutation in a transfection system.  
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To minimize the effects of selection, we transfected a Norwalk virus infectious cDNA clone into 
HEK293 cells expressing the T7 RNA polymerase from a recombinant vaccinia virus (ATCC VR-
2153). As previously described, this system supports NoV transcription, replication and 
encapsidation (Fig. 1B), but does not allow released virions to initiate a second infection cycle 
because HEK293T are not a natural cell target for the virus (Asanaka et al. 2005). After 48 h 
incubation, total RNA was extracted from cells, residual DNA was removed with DNAse I, a 
specific primer annealing to the minus-strand of the VP1 capsid gene was used for reverse 
transcription, and high-fidelity PCR amplification of a region encompassing positions 19 to 323 
of the VP1 gene (305 bases, although only the 266 bases excluding primer regions were 
considered for subsequent analysis) was carried out. For each of three independent 
transfection assays, we subjected the PCR products to paired-end Illumina sequencing with the 
same coverage as above. Comparison of Illumina reads with the sequence of the infectious 
cDNA clone (reference sequence: GenBank NC_001959) revealed hundreds of sequences with 
multiple U-to-C substitutions.  Some examples of U-to-C hyper-mutants are shown in Fig. 2. To 
objectively define hyper-mutated sequences, we analyzed the distribution of the number of U-
to-C transitions among the 100,000 reads obtained for each replicate assay.  The distribution 
clearly deviated from a Poisson model of rare random events, showing an excess of sequences 
with high mutation counts (Fig. 3A). Based on this, we defined hyper-mutated sequences as 
those carrying five or more mutations in the 266-base region studied. However, the data also 
showed that hyper-mutation was not an all-or-nothing process and that the number of 
mutations per read varied continuously. Regarding U-to-C substitutions, we found 1444 hyper-
mutated reads (266, 481 and 697 reads for assays 1, 2 and 3, respectively), meaning that 
approximately one every 200 reads (0.48%) contained U-to-C hyper-mutations (Table 2). These 
carried 11,612 total U-to-C substitutions, the number of mutations per read varying from 5 to 
31 out of the 88 U residues contained in the 266-base fragment.  Since sequences were 
derived from minus-strand RNA, U-to-C substitutions in the reference (plus-strand) genome 
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sequence indicate that the negative-strand template RNA contained A-to-G substitutions. 
Ultra-deep sequencing also revealed some A-to-G hyper-mutated sequences in two of the 
three assays (indicating U-to-C changes in the negative-strand template), but these were 17 
times less frequent (i.e. 1444/83 = 17.4) than the former (Table 2). A-to-G hyper-mutants may 
be a result of plus-strand carry-over amplification during RT-PCR or, alternatively, they may 
represent a different mutational process. 
3.3. Reproducible effect of sequence context on hyper-mutation.   
Analysis of the location of mutations revealed a widespread distribution along the 266-base 
VP1 region. Although all of the 88 U residues showed at least one U-to-C mutation at this high 
sequencing depth, mutation frequencies varied strongly across sites, the pattern of variation 
being highly reproducible between the three biological replicates (pairwise Spearman  > 
0.850, p < 10– 12; Fig. 3B). A major determinant of the frequency of U-to-C mutation was the 
identity of the 3´neighboring base. Among the 11,612 U-to-C changes observed, the 
3´neighbor was U in 5228 cases, A in 5053 cases, G in 1098 cases, and C in only 233 cases. 
These counts clearly deviated from those of 3´neighbors of non-mutated bases (chi-square 
test: p < 10–12; Fig. 3C). After correcting for base composition, the 3´neighbor preferences for 
U-to-C hyper-mutation were A > U > G > C. Interestingly, A-to-G hyper-mutated sequences 
showed a marked bias in the 5´neighboring base such that, among the 638 total A-to-G 
mutations, the 5´neighbor was U in 379 cases, A in 204 cases, G in 14 cases, and C in 41 cases 
(p < 10–12; Fig. 3C). Therefore, A-to-G hyper-mutation had 5´neighbor base preferences (U > A > 
C > G) which are exactly the reverse complement of those for U-to-C hyper-mutation. This 
strongly suggests a common biochemical process underlying both U-to-C and A-to-G 
mutations, the type of change observed depending on whether hyper-mutation occurred in 
the minus or plus RNA strand, respectively. 
3.4. Contribution of hyper-mutation to the total NoV rate of spontaneous mutation.  
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Based on the above data, the per-base probability of a U-to-C substitution due to hyper-
mutation was (1.5 ± 0.4) × 10–4, a value within the typical range of RNA virus rates of 
spontaneous mutation (Lauring et al. 2013; Sanjuán et al. 2010). To ascertain the contribution 
of hyper-mutation events to the total NoV mutation rate, we sought to estimate the total 
mutation rate from the above single-cycle transfection assays. Since the Illumina per-read 
accuracy is not high enough to reliably infer individual base substitutions at such low 
frequencies, we performed classical molecular cloning followed by Sanger sequencing.  Using 
RNA extracts from the above transfections, we amplified by high-fidelity RT-PCR the entire VP1 
gene and obtained 64 molecular clones. In total, we found 21 base substitutions in 136,032 
bases, giving a mutation rate estimate of 1.5 × 10–4 per nucleotide per cell infection (Table 3), a 
value nearly identical to the hyper-mutation rate inferred by Illumina sequencing. 
Furthermore, of the 21 mutations 18 were U-to-C base transitions found in a single, hyper-
mutated clone. Removing this single clone, the estimated mutation rate was 2.2 × 10–5, a value 
seven times lower than the estimated hyper-mutation rate.  
 
4. Discussion 
Our results reveal that a large fraction of NoV spontaneous mutations is constituted by U-to-C 
and A-to-G substitutions occurring as bouts of mutations in the same RNA molecule.  We argue 
that, depending on whether the hyper-mutation takes place in the minus or plus strand, U-to-C 
or A-to-G changes are observed, respectively, in the (plus strand) genomic RNA. A likely 
mechanism underlying these A-to-G mutations is ADAR, which edits adenosines to inosines 
that subsequently base-pair with cytosines (Samuel 2011; Valente and Nishikura 2005). A 
hallmark of ADAR 1 and 2 is that editing is more likely when the 5´ neighbor of the editable 
base is A or U and, more precisely, the neighbor base preferences have been shown to be U > 
A > C > G (Dawson et al. 2004; Kuttan and Bass 2012; Lehmann and Bass 2000; Polson and Bass 
1994). Our sequence analysis shows exactly these same preferences, thus supporting the 
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involvement of ADAR in NoV hyper-mutation. Previous work has shown or suggested ADAR-
mediated hyper-mutation in several viruses, but these were negative-strand viruses as 
opposed to NoVs (Samuel 2011). Hyper-mutation should be carried out by the interferon-
inducible p150 isoform of ADAR1, since this is the only ADAR form located in the cytoplasm 
(George et al. 2011) where NoVs replicate. ADAR uses double-stranded RNA as substrate and, 
therefore, the template RNA has to adopt a nearly perfect stem-like secondary structure or be 
a double-stranded replicative intermediate. The secondary structure of the NoV genomic RNA 
has not been solved experimentally and, although in silico RNA folding shows limited reliability 
for long molecules, stem-like structures are simple enough to be confidently predicted. 
However, the minimum free energy structure of the 266-base region encompassing VP1 
nucleotides 38 to 303 predicted by the mfold algorithm (Zuker 2003) did not show a stem-like 
structure. This suggests that ADAR acts on NoV double-stranded replicative intermediates. 
ADAR 1 is ubiquitously expressed in human tissues (Kim et al. 1994) and, although HEK293 cells 
express relatively low ADAR 1 levels, this activity was shown to be sufficient to edit 5% of 
hepatitis delta virus RNA molecules (Sato et al. 2001). In B lymphocytes, which are a candidate 
cell target for NoVs in vivo (Jones et al. 2014), ADAR1 and ADAR2 are more strongly expressed 
and have been shown to edit thousands of adenosines in cellular mRNA and long non-coding 
RNA (Wang et al. 2013). 
A limitation of our study is that, whereas transfection assays were carried out using a 
cDNA clone belonging to genogroup I, viruses isolated from stool samples were all from 
genogroup II. However, the type of mutations produced and the neighbor base preferences 
were very similar in stool samples and in transfection assays. Specifically, 82.9% of the 5´ 
neighbors of U-to-C mutations and 72.3% of the 3´ neighbors of A-to-G mutations were A or U 
in clinical samples. After correcting for base composition, the resulting 3´neighbor preferences 
for U-to-C mutations were A > U > G > C, whereas the 5´preferences for A-to-G mutations were 
U > A > G > C in clinical samples. The similarities between the results obtained in transfection 
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assays and in vivo support a common underlying mechanism, despite the fact that different 
genogroups were used for these experiments. Still, hyper-mutation was 30-fold more 
abundant in the transfection assays than in clinical samples. We attribute this difference to the 
fact that selection was mild or absent in transfection assays, whereas in stool samples (which 
should contain mainly free virions) we expect stronger selection against hyper-mutated 
genomes. Alternatively, it is possible that ADAR activity was lower in the NoV target cells in 
vivo than in HEK293 cells. However, B cells show extensive ADAR-mediated editing of cellular 
RNAs (Wang et al. 2013). Work with HIV-1 has shown that the observed levels of hyper-
mutation vary depending on whether intra-cellular or virion-associated sequences are 
analyzed (Russell et al. 2009). APOBEC massively edits the retroviral cDNA, leading to a rate of 
G-to-A mutation of approximately 4 × 10–3 per base per cell, a value two orders of magnitude 
higher than HIV-1 reverse transcriptase errors (Cuevas et al. 2015). In contrast, the rate 
observed in plasma is 44 times lower, consistent with the notion that the vast majority of 
APOBEC-edited HIV-1 genomes are unviable and rapidly removed by selection (Ho et al. 2013). 
In human hepatitis B virus, papilloma virus, herpes simplex virus 1 and Epstein-Barr virus 
APOBEC-edited genomes are usually found at low frequencies and their identification required 
a modified PCR protocol in which the lower melting temperature of A/T-rich molecules is 
exploited for selective amplification of hyper-mutants (Suspene et al. 2011; Suspene et al. 
2005; Vartanian et al. 2008). A variant of this strategy has been devised for ADAR-edited 
sequences, which allowed detecting hyper-mutants in Rift Valley virus (Suspene et al. 2008). 
Therefore, probably with the exception of HIV-1, hyper-mutated sequences are generally rare. 
Selective PCR amplification is valuable for detecting these sequences but does not allow 
estimation of their population frequency. As a result, few studies have determined the 
abundance of viral hyper-mutants in an unbiased manner. Ultra-deep sequencing provides a 
powerful tool for achieving this goal. 
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5. Conclusions  
Previous work has suggested that the high genetic diversity of RNA viruses originates mainly 
from the low replication fidelity of their polymerases. However, our in depth analysis of NoV 
spontaneous mutations in clinical samples and laboratory populations supports the notion that 
host-driven hyper-mutation is a source of diversity comparable to or even greater than 
polymerase infidelity. Hyper-mutation is not necessarily an all-or-nothing process and the 
number of nucleotide substitutions per sequence varied extensively, suggesting that hyper-
mutation may significantly contribute to NoV genetic diversity and evolution in nature. 
Analysis of the types of mutations produced in longitudinal studies may help elucidate this 
contribution. 
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Table 1. Hyper-mutant (HM) sequences found in stool samples after RT-PCR of two VP1 regions. 
1Reads with an average base quality (Sanger-scaled Phred) score Q > 28 at mutated positions. 
2RT-PCR failed. 
  
 Region 1 (341 bases) Region 2 (409 bases) 
Sample Total 
reads1 
HM  
type 
HM 
reads 
Mutations/read 
(mean, min, max) 
Total 
reads1 
HM 
type 
HM 
reads 
Mutations/read 
(mean, min, max) 
3106 99176 A-to-G 12 7.2 (5-10) 96415 U-to-C 39 5.5 (5-7) 
3142 97757 U-to-C 27 10.6 (5-30) N/A2 - - - 
3210 N/A2 - - - 96770 U-to-C 13 5.6 (5-6) 
3213 98967 A-to-G 13 7.8 (5-12) 95936 A-to-G 8 17.5 (6-37) 
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Table 2. Hyper-mutant (HM) VP1 sequences (bases 38-303) derived from transfected HEK293 cells. 
1Reads with an average base quality (Sanger-scaled Phred) score Q > 28 at mutated positions. 
2Mutation rates were estimated by dividing, for a giving assay, the total number of mutations by the product 
of reads times the length of the PCR product (266 bases). 
  
Assay NGS valid 
reads1 
U-to-C HM A-to-G HM 
Number of 
reads 
Mutations/read 
(mean, min, max) 
Mutation 
rate2 
Number of 
reads 
Mutations/read 
(mean, min, max) 
Mutation 
rate2 
1 99,982 266 8.7 (5-28) 8.7 × 10–5 67 7.8 (5-14) 2.0 × 10–5 
2 99,917 481 8.0 (5-20) 1.4 × 10–4 0 NA 0 
3 99,973 697 9.2(5-31) 2.1 × 10–4 16 7.1 (5-18) 4.3 × 10–6 
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Table 3. Mutations found by Sanger sequencing in NoV VP1 molecular clones derived from 
transfected HEK293 cells. 
 
 
 
 
 
 
 
  
 Total Without hyper-mutant 
VP1 clones sequenced 64 63 
Total bases sequenced 136,032 133,901 
Total mutations 21 3 
U-to-C substitutions 18 0 
Total mutation frequency 1.5 × 10–4 2.2 × 10–5 
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Figure legends 
Fig. 1. NoV genetic map, regions sequenced, and setup of transfection assays. A. In the NoV 
genetic map, the VP1 capsid gene is shown in red. Molecular clones encompassing the entire 
VP1 gene were sequenced by the Sanger method. Illumina sequencing was used to analyse 
smaller regions mapping to the S domain of VP1 and the hyper-variable domain P2 (dark red 
bars). B. An infectious cDNA clone was transfected in HEK293 cells previously infected with a 
recombinant vaccinia virus expressing T7 RNA polymerase, allowing for transcription of plus-
strand NoV genomic RNA. A primer annealing to minus-strand copies was used for RT-PCR 
amplification and sequencing. Colored circles represent mutations/variants. 
 
Fig. 2. Distribution of U-to-C mutations along a VP1 region in sequences derived from 
transfected HEK293 cells. The alignment on top shows two examples of highly mutated reads 
from each transfection assay. The heat map below indicates, for each nucleotide site, the total 
number of deep-sequencing reads carrying a U-to-C mutation (see color legend). 
 
Fig. 3. Analysis of hyper-mutation patterns. A. Distribution of the number of U-to-C mutations 
per deep sequencing read in each of the three transfection assays. The red histograms show 
the observed counts and the blue line indicates the counts expected from a Poisson model of 
rare random events. The single parameter of the Poisson distribution was calibrated using the 
number of reads carrying zero or one mutations. The strong deviation between observed and 
expected counts shows that sequence reads carrying multiple mutations were more frequent 
than expected from the Poisson model. Based on this, hyper-mutated reads were defined as 
those carrying five or more mutations. B. Reproducibility of U-to-C mutation frequency in 
three transfection assays. In the graphs, each data point corresponds to an U-containing 
nucleotide site, and the number of times a U-to-C mutation was observed in deep-sequencing 
reads is plotted for each pair of transfection assays (also represented in the heat map of Fig. 
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2). From left to right, Spearman correlations were 0.860, 0.855, and 0.955 (p < 10–12 in all 
cases). C. Neighbor base preferences for U-to-C and A-to-G hyper-mutation. The histograms 
show the frequency of U, A, G, and C among 3´neighbors of U-to-C mutations (left), and the 
frequency of U, A, G, and C among 5´neighbors of A-to-G mutations (right). The crossed lines 
indicate these same frequencies among non-mutated bases (null expectation). The error bars 
indicate the SEM frequency from three transfection assays.  
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Highlights 
- Norovirus U-to-C hyper-mutants are present in patient samples 
- Analysis of hyper-mutants in cell culture suggests ADAR-mediated RNA edition 
- Hyper-mutation may contribute to norovirus diversity and evolution 
